Filing Flows › Immunome (IMNM) › Q4 2024
Immunome (IMNM) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 19, 2025
Immunome (IMNM) reported revenue of $2.7M for the fourth quarter 2024 (Q4 2024), -28% from a year earlier and -6% from the quarter before.
Immunome, Q4 2024: revenue $2.7M (-28% year over year), net loss $80.2M, operating cash flow −$42.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.7M | -6% | -28% |
| Operating profit | −$83.0M | — | — |
| Net earnings | −$80.2M | — | — |
| Operating cash flow | −$42.1M | — | — |
What changed
Revenue was $2.7M in Q4 2024, down 28% year over year and down 6% from the previous quarter.
Operating costs exceeded revenue by $83.0M, an operating margin of -3030.3%. Total costs fell 13% while revenue fell 28%. The fastest-growing cost line was Research & development (+397%). The quarter ended with a net loss of $80.2M, wider than the previous quarter's $47.1M loss.
Operating cash flow was −$42.1M. Non-cash charges added back $450K of depreciation and amortization and $5.5M of share-based compensation. Working capital and other items added $32.3M. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$43.2M.
Questions
What was Immunome's revenue in the fourth quarter 2024?
Immunome (IMNM) reported revenue of $2.7M for the fourth quarter 2024 (Q4 2024), -28% from a year earlier and -6% from the quarter before.
Source: Immunome 10-K on SEC EDGAR.